BHCM
SGMT icon

Brevan Howard Capital Management’s Sagimet Biosciences SGMT Stock Holding History

Brevan Howard Capital Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$109K Buy
+20,905
New +$117K ﹤0.01% 2004

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Brevan Howard Capital Management's SGMT Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in Sagimet Biosciences (SGMT) in Q1 2026: 20,905 shares worth $109K. The stake represents ﹤0.01% of the portfolio and ranks #2004 among its holdings.

88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Brevan Howard Capital Management held 20,905 shares of Sagimet Biosciences worth $109K as of Q1 2026.
  • Sagimet Biosciences was a new Brevan Howard Capital Management position in Q1 2026.
  • Sagimet Biosciences made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #2004 holding.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.